SFF
The pandemic offered many valuable lessons to pharma’s sterile fill and finish contractors, including how to refine processes to manufacture mRNA vaccines safely and dispense them to billions of patients at a record pace. The industry and its contract service providers proved more than equal to the challenge. In a recent article with Contract Pharma, Recipharm’s Jon Reed highlights how collaboration and process innovation helped accelerate development and commercialisation of two critical programs.
Some of the key topics discussed include:
- The lessons learnt by the industry
- How flexibility helped achieve commercialization at an unprecedented pace
- Increasing the safety and mobility of vaccines
- A future outlook
Perhaps the most crucial lesson being learned post-pandemic was just how valuable the collaboration with contract development and manufacturing organisations (CDMOs) turned out to be. By leveraging messenger RNA (mRNA) technology and commercial manufacturing partnerships, pharma companies were able to accelerate development and deliver an effective mRNA-based response to the virus.
